{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:03:09Z","timestamp":1787162589298,"version":"build-2736575974"},"reference-count":108,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":1421,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002243","name":"National Ataxia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002243","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["R01 NS085054"],"award-info":[{"award-number":["R01 NS085054"]}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s13311-019-00763-y","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T13:03:45Z","timestamp":1563887025000},"page":"999-1008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Moving Towards Therapy in SCA1: Insights from Molecular Mechanisms, Identification of Novel Targets, and Planning for Human Trials"],"prefix":"10.1016","volume":"16","author":[{"given":"Sharan R.","family":"Srinivasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2742-6469","authenticated-orcid":false,"given":"Vikram G.","family":"Shakkottai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1007\/s13311-019-00763-y_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ncl.2013.04.006","article-title":"Clinical neurogenetics: autosomal dominant spinocerebellar ataxia","volume":"31","author":"Shakkottai","year":"2013","journal-title":"Neurol Clin"},{"issue":"9","key":"10.1007\/s13311-019-00763-y_bib2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(10)70183-6","article-title":"Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond","volume":"9","author":"Durr","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-019-00763-y_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1750-1172-8-177","article-title":"Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study","volume":"8","author":"Ashizawa","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"10.1007\/s13311-019-00763-y_bib4","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1474-4422(15)00202-1","article-title":"Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study","volume":"14","author":"Jacobi","year":"2015","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1007\/s13311-019-00763-y_bib5","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/BF00318569","article-title":"Structural and immunocytochemical features of olivopontocerebellar atrophy caused by the spinocerebellar ataxia type 1 (SCA-1) mutation define a unique phenotype","volume":"90","author":"Robitaille","year":"1995","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1007\/s13311-019-00763-y_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-012-1000-x","article-title":"Brain pathology of spinocerebellar ataxias","volume":"124","author":"Seidel","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"12","key":"10.1007\/s13311-019-00763-y_bib7","first-page":"5765","article-title":"Cognitive impairments in patients with spinocerebellar ataxia types 1, 2 and 3 are positively correlated to the clinical severity of ataxia symptoms","volume":"7","author":"Ma","year":"2014","journal-title":"Int J Clin Exp Med"},{"issue":"1\u20132","key":"10.1007\/s13311-019-00763-y_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1155\/2010\/395045","article-title":"A preliminary characterisation of cognition and social cognition in spinocerebellar ataxia types 2, 1, and 7","volume":"23","author":"Sokolovsky","year":"2010","journal-title":"Behav Neurol"},{"issue":"7","key":"10.1007\/s13311-019-00763-y_bib9","doi-asserted-by":"crossref","first-page":"e1003648","DOI":"10.1371\/journal.pgen.1003648","article-title":"The role of interruptions in polyQ in the pathology of SCA1","volume":"9","author":"Menon","year":"2013","journal-title":"PLoS Genet"},{"issue":"1","key":"10.1007\/s13311-019-00763-y_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/hmg\/10.1.25","article-title":"The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract","volume":"10","author":"Yue","year":"2001","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1007\/s13311-019-00763-y_bib11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.cell.2006.11.038","article-title":"ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology","volume":"127","author":"Lam","year":"2006","journal-title":"Cell"},{"issue":"4","key":"10.1007\/s13311-019-00763-y_bib12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2005.06.012","article-title":"The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1\/Senseless proteins","volume":"122","author":"Tsuda","year":"2005","journal-title":"Cell"},{"issue":"1","key":"10.1007\/s13311-019-00763-y_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0092-8674(00)81781-X","article-title":"Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice","volume":"95","author":"Klement","year":"1998","journal-title":"Cell"},{"issue":"Pt 1","key":"10.1007\/s13311-019-00763-y_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1242\/jcs.01611","article-title":"RNA association and nucleocytoplasmic shuttling by ataxin-1","volume":"118","author":"Irwin","year":"2005","journal-title":"J Cell Sci"},{"issue":"6","key":"10.1007\/s13311-019-00763-y_bib15","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.neuron.2010.08.022","article-title":"SCA1-like disease in mice expressing wild-type ataxin-1 with a serine to aspartic acid replacement at residue 776","volume":"67","author":"Duvick","year":"2010","journal-title":"Neuron"},{"issue":"3","key":"10.1007\/s13311-019-00763-y_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0896-6273(03)00258-7","article-title":"Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice","volume":"38","author":"Emamian","year":"2003","journal-title":"Neuron"},{"issue":"2","key":"10.1007\/s13311-019-00763-y_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/hmg\/dds427","article-title":"Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2","volume":"22","author":"Hansen","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"36","key":"10.1007\/s13311-019-00763-y_bib18","doi-asserted-by":"crossref","first-page":"13002","DOI":"10.1523\/JNEUROSCI.2789-11.2011","article-title":"Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3","volume":"31","author":"Shakkottai","year":"2011","journal-title":"J Neurosci"},{"issue":"5","key":"10.1007\/s13311-019-00763-y_bib19","doi-asserted-by":"crossref","first-page":"e0198040","DOI":"10.1371\/journal.pone.0198040","article-title":"Dendritic potassium channel dysfunction may contribute to dendrite degeneration in spinocerebellar ataxia type 1","volume":"13","author":"Chopra","year":"2018","journal-title":"PLoS One"},{"issue":"15","key":"10.1007\/s13311-019-00763-y_bib20","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/mds.22288","article-title":"Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6","volume":"23","author":"Globas","year":"2008","journal-title":"Mov Disord"},{"issue":"21","key":"10.1007\/s13311-019-00763-y_bib21","doi-asserted-by":"crossref","first-page":"123193","DOI":"10.1172\/jci.insight.123193","article-title":"Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles.","volume":"3","author":"Friedrich","year":"2018","journal-title":"JCI Insight,"},{"key":"10.1007\/s13311-019-00763-y_bib22","doi-asserted-by":"crossref","first-page":"e39981","DOI":"10.7554\/eLife.39981","article-title":"Molecular pathway analysis towards understanding tissue vulnerability in spinocerebellar ataxia type 1.","volume":"7","author":"Driessen","year":"2018","journal-title":"eLife,"},{"issue":"24","key":"10.1007\/s13311-019-00763-y_bib23","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1007\/s13311-019-00763-y_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/17425240902758188","article-title":"Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases","volume":"6","author":"Barchet","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"issue":"40","key":"10.1007\/s13311-019-00763-y_bib25","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1523\/JNEUROSCI.2978-04.2004","article-title":"Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice","volume":"24","author":"Zu","year":"2004","journal-title":"J Neurosci"},{"issue":"6","key":"10.1007\/s13311-019-00763-y_bib26","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1172\/JCI96765","article-title":"Mutant ataxin1 disrupts cerebellar development in spinocerebellar ataxia type 1","volume":"128","author":"Edamakanti","year":"2018","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1007\/s13311-019-00763-y_bib27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.nbt.2013.01.005","article-title":"Advances in therapeutic RNA-targeting","volume":"30","author":"van Ommen","year":"2013","journal-title":"New Biotechnol"},{"issue":"5","key":"10.1007\/s13311-019-00763-y_bib28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol"},{"issue":"18","key":"10.1007\/s13311-019-00763-y_bib29","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"7650","key":"10.1007\/s13311-019-00763-y_bib30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature22044","article-title":"Antisense oligonucleotide therapy for spinocerebellar ataxia type 2","volume":"544","author":"Scoles","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1007\/s13311-019-00763-y_bib31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/ana.25264","article-title":"Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice","volume":"84","author":"McLoughlin","year":"2018","journal-title":"Ann Neurol"},{"issue":"24","key":"10.1007\/s13311-019-00763-y_bib32","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin Expression in Patients with Huntington's Disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1007\/s13311-019-00763-y_bib33","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/nsmb.3486","article-title":"Class 2 CRISPR-Cas RNA-guided endonucleases: Swiss Army knives of genome editing","volume":"24","author":"Stella","year":"2017","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"10.1007\/s13311-019-00763-y_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.molcel.2017.09.007","article-title":"The Revolution Continues: Newly Discovered Systems Expand the CRISPR-Cas Toolkit","volume":"68","author":"Murugan","year":"2017","journal-title":"Mol Cell"},{"issue":"1","key":"10.1007\/s13311-019-00763-y_bib35","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv"},{"issue":"1","key":"10.1007\/s13311-019-00763-y_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrmicro.2017.120","article-title":"Anti-CRISPR: discovery, mechanism and function","volume":"16","author":"Pawluk","year":"2018","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1007\/s13311-019-00763-y_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2017.09.002","article-title":"The Anti-CRISPR Story: A Battle for Survival","volume":"68","author":"Maxwell","year":"2017","journal-title":"Mol Cell"},{"issue":"10","key":"10.1007\/s13311-019-00763-y_bib38","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/nn.2183","article-title":"miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis","volume":"11","author":"Lee","year":"2008","journal-title":"Nat Neurosci"},{"issue":"12","key":"10.1007\/s13311-019-00763-y_bib39","doi-asserted-by":"crossref","first-page":"2316 e2317","DOI":"10.1016\/j.neurobiolaging.2010.03.014","article-title":"Genome-wide analysis of miRNA expression reveals a potential role for miR-144 in brain aging and spinocerebellar ataxia pathogenesis","volume":"32","author":"Persengiev","year":"2011","journal-title":"Neurobiol Aging"},{"issue":"5","key":"10.1007\/s13311-019-00763-y_bib40","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ana.24789","article-title":"RNAi prevents and reverses phenotypes induced by mutant human ataxin-1","volume":"80","author":"Keiser","year":"2016","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1007\/s13311-019-00763-y_bib41","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nm1076","article-title":"RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia","volume":"10","author":"Xia","year":"2004","journal-title":"Nat Med"},{"issue":"3","key":"10.1007\/s13311-019-00763-y_bib42","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/mt.2013.279","article-title":"Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy","volume":"22","author":"Keiser","year":"2014","journal-title":"Mol Ther"},{"issue":"14","key":"10.1007\/s13311-019-00763-y_bib43","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1523\/JNEUROSCI.18-14-05508.1998","article-title":"Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation","volume":"18","author":"Matilla","year":"1998","journal-title":"J Neurosci"},{"issue":"7","key":"10.1007\/s13311-019-00763-y_bib44","doi-asserted-by":"crossref","first-page":"e1001021","DOI":"10.1371\/journal.pgen.1001021","article-title":"Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis","volume":"6","author":"Crespo-Barreto","year":"2010","journal-title":"PLoS Genet"},{"issue":"7188","key":"10.1007\/s13311-019-00763-y_bib45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nature06731","article-title":"Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1","volume":"452","author":"Lim","year":"2008","journal-title":"Nature"},{"issue":"33","key":"10.1007\/s13311-019-00763-y_bib46","doi-asserted-by":"crossref","first-page":"11795","DOI":"10.1523\/JNEUROSCI.0905-11.2011","article-title":"Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1","volume":"31","author":"Hourez","year":"2011","journal-title":"J Neurosci"},{"issue":"32","key":"10.1007\/s13311-019-00763-y_bib47","doi-asserted-by":"crossref","first-page":"11292","DOI":"10.1523\/JNEUROSCI.1357-15.2015","article-title":"Neuronal Atrophy Early in Degenerative Ataxia Is a Compensatory Mechanism to Regulate Membrane Excitability","volume":"35","author":"Dell'Orco","year":"2015","journal-title":"J Neurosci"},{"issue":"10","key":"10.1007\/s13311-019-00763-y_bib48","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.chembiol.2012.07.013","article-title":"Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2","volume":"19","author":"Kasumu","year":"2012","journal-title":"Chem Biol"},{"issue":"20","key":"10.1007\/s13311-019-00763-y_bib49","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1093\/hmg\/ddx281","article-title":"Potassium channel dysfunction underlies Purkinje neuron spiking abnormalities in spinocerebellar ataxia type 2","volume":"26","author":"Dell'Orco","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"25","key":"10.1007\/s13311-019-00763-y_bib50","doi-asserted-by":"crossref","first-page":"9474","DOI":"10.1073\/pnas.0401702101","article-title":"Cerebellar ataxia and Purkinje cell dysfunction caused by Ca2+\u2212activated K+ channel deficiency","volume":"101","author":"Sausbier","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 1","key":"10.1007\/s13311-019-00763-y_bib51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1113\/jphysiol.2002.027854","article-title":"Distinct contributions of small and large conductance Ca2+\u2212activated K+ channels to rat Purkinje neuron function","volume":"548","author":"Edgerton","year":"2003","journal-title":"J Physiol"},{"issue":"3","key":"10.1007\/s13311-019-00763-y_bib52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/acn3.527","article-title":"Targeting potassium channels to treat cerebellar ataxia","volume":"5","author":"Bushart","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"10.1007\/s13311-019-00763-y_bib53","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.44.6.1054","article-title":"The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial","volume":"44","author":"Bever","year":"1994","journal-title":"Neurology"},{"issue":"9665","key":"10.1007\/s13311-019-00763-y_bib54","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"key":"10.1007\/s13311-019-00763-y_bib55","doi-asserted-by":"crossref","first-page":"29489","DOI":"10.1038\/srep29489","article-title":"4-aminopyridine reverses ataxia and cerebellar firing deficiency in a mouse model of spinocerebellar ataxia type 6","volume":"6","author":"Jayabal","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1007\/s13311-019-00763-y_bib56","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0026-895X(25)10594-4","article-title":"Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines","volume":"45","author":"Grissmer","year":"1994","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1007\/s13311-019-00763-y_bib57","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/ng1758","article-title":"Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes","volume":"38","author":"Waters","year":"2006","journal-title":"Nat Genet"},{"issue":"1","key":"10.1007\/s13311-019-00763-y_bib58","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0006-8993(02)03730-7","article-title":"Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells","volume":"959","author":"Liu","year":"2003","journal-title":"Brain Res"},{"issue":"3","key":"10.1007\/s13311-019-00763-y_bib59","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0022-3565(24)38803-2","article-title":"Modulation of recombinant small-conductance Ca(2+)-activated K(+) channels by the muscle relaxant chlorzoxazone and structurally related compounds","volume":"296","author":"Cao","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"Pt 2","key":"10.1007\/s13311-019-00763-y_bib60","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1113\/jphysiol.2004.081000","article-title":"GABAergic activation of an inwardly rectifying K+ current in mouse cerebellar Purkinje cells","volume":"563","author":"Tabata","year":"2005","journal-title":"J Physiol"},{"issue":"2","key":"10.1007\/s13311-019-00763-y_bib61","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/mol.108.051425","article-title":"Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure","volume":"75","author":"Sankaranarayanan","year":"2009","journal-title":"Mol Pharmacol"},{"issue":"9","key":"10.1007\/s13311-019-00763-y_bib62","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group","volume":"330","author":"Bensimon","year":"1994","journal-title":"N Engl J Med"},{"issue":"9013","key":"10.1007\/s13311-019-00763-y_bib63","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"issue":"2","key":"10.1007\/s13311-019-00763-y_bib64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/PL00005241","article-title":"Riluzole, a glutamate release inhibitor, and motor behavior","volume":"358","author":"Kretschmer","year":"1998","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"5","key":"10.1007\/s13311-019-00763-y_bib65","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.bjp.0705491","article-title":"Riluzole inhibits spontaneous Ca2+ signaling in neuroendocrine cells by activation of K+ channels and inhibition of Na+ channels","volume":"140","author":"Beltran-Parrazal","year":"2003","journal-title":"Br J Pharmacol"},{"issue":"1\u20132","key":"10.1007\/s13311-019-00763-y_bib66","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0014-2999(02)01987-8","article-title":"Modulation of recombinant and native neuronal SK channels by the neuroprotective drug riluzole","volume":"449","author":"Cao","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"10.1007\/s13311-019-00763-y_bib67","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1212\/WNL.0b013e3181d31e23","article-title":"Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial","volume":"74","author":"Ristori","year":"2010","journal-title":"Neurology"},{"issue":"10","key":"10.1007\/s13311-019-00763-y_bib68","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S1474-4422(15)00201-X","article-title":"Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Romano","year":"2015","journal-title":"Lancet Neurol"},{"issue":"7454","key":"10.1007\/s13311-019-00763-y_bib69","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nature12204","article-title":"RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1","volume":"498","author":"Park","year":"2013","journal-title":"Nature"},{"issue":"12","key":"10.1007\/s13311-019-00763-y_bib70","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1074\/jbc.R800041200","article-title":"Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1","volume":"284","author":"Zoghbi","year":"2009","journal-title":"J Biol Chem"},{"issue":"16","key":"10.1007\/s13311-019-00763-y_bib71","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1093\/hmg\/ddy200","article-title":"PAK1 regulates ATXN1 levels providing an opportunity to modify its toxicity in spinocerebellar ataxia type 1","volume":"27","author":"Bondar","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-019-00763-y_bib72","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fnins.2015.00403","article-title":"Potential application of lithium in Parkinson's and other neurodegenerative diseases","volume":"9","author":"Lazzara","year":"2015","journal-title":"Front Neurosci"},{"issue":"6","key":"10.1007\/s13311-019-00763-y_bib73","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1021\/cn5000309","article-title":"Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders","volume":"5","author":"Forlenza","year":"2014","journal-title":"ACS Chem Neurosci"},{"issue":"5","key":"10.1007\/s13311-019-00763-y_bib74","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1371\/journal.pmed.0040182","article-title":"Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model","volume":"4","author":"Watase","year":"2007","journal-title":"PLoS Med"},{"issue":"1","key":"10.1007\/s13311-019-00763-y_bib75","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00415-014-7551-0","article-title":"A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2","volume":"262","author":"Sacca","year":"2015","journal-title":"J Neurol"},{"issue":"4","key":"10.1007\/s13311-019-00763-y_bib76","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/mds.25803","article-title":"A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease","volume":"29","author":"Saute","year":"2014","journal-title":"Mov Disord"},{"issue":"11","key":"10.1007\/s13311-019-00763-y_bib77","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/nm.2494","article-title":"Vascular endothelial growth factor ameliorates the ataxic phenotype in a mouse model of spinocerebellar ataxia type 1","volume":"17","author":"Cvetanovic","year":"2011","journal-title":"Nat Med"},{"issue":"2","key":"10.1007\/s13311-019-00763-y_bib78","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/brain\/awy328","article-title":"Self-assembling vascular endothelial growth factor nanoparticles improve function in spinocerebellar ataxia type 1","volume":"142","author":"Hu","year":"2019","journal-title":"Brain"},{"issue":"1","key":"10.1007\/s13311-019-00763-y_bib79","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nn1360","article-title":"Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.","volume":"8","author":"Storkebaum","year":"2005","journal-title":"Nat Neurosci"},{"issue":"22","key":"10.1007\/s13311-019-00763-y_bib80","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1212\/01.wnl.0000335970.78664.36","article-title":"Subcutaneous IGF-1 is not beneficial in 2-year ALS trial","volume":"71","author":"Sorenson","year":"2008","journal-title":"Neurology"},{"issue":"18","key":"10.1007\/s13311-019-00763-y_bib81","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1523\/JNEUROSCI.3953-15.2016","article-title":"Prolonged Type 1 Metabotropic Glutamate Receptor Dependent Synaptic Signaling Contributes to Spino-Cerebellar Ataxia Type 1","volume":"36","author":"Power","year":"2016","journal-title":"J Neurosci"},{"issue":"1","key":"10.1007\/s13311-019-00763-y_bib82","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1113\/JP272950","article-title":"Progressive impairment of cerebellar mGluR signalling and its therapeutic potential for cerebellar ataxia in spinocerebellar ataxia type 1 model mice","volume":"595","author":"Shuvaev","year":"2017","journal-title":"J Physiol"},{"key":"10.1007\/s13311-019-00763-y_bib83","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1756-6606-6-48","article-title":"Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1","volume":"6","author":"Notartomaso","year":"2013","journal-title":"Mol Brain"},{"issue":"3","key":"10.1007\/s13311-019-00763-y_bib84","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.celrep.2014.09.042","article-title":"A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease","volume":"9","author":"Brehme","year":"2014","journal-title":"Cell Rep"},{"issue":"7356","key":"10.1007\/s13311-019-00763-y_bib85","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature10317","article-title":"Molecular chaperones in protein folding and proteostasis","volume":"475","author":"Hartl","year":"2011","journal-title":"Nature"},{"issue":"Suppl 4","key":"10.1007\/s13311-019-00763-y_bib86","doi-asserted-by":"crossref","first-page":"16412","DOI":"10.1073\/pnas.182426899","article-title":"Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity","volume":"99","author":"Sakahira","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1007\/s13311-019-00763-y_bib87","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/138920110790909650","article-title":"Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases","volume":"11","author":"Nagai","year":"2010","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1007\/s13311-019-00763-y_bib88","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnmol.2017.00078","article-title":"The Ubiquitination, Disaggregation and Proteasomal Degradation Machineries in Polyglutamine Disease","volume":"10","author":"Nath","year":"2017","journal-title":"Front Mol Neurosci"},{"issue":"8","key":"10.1007\/s13311-019-00763-y_bib89","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1007\/s12035-016-0120-z","article-title":"Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders","volume":"54","author":"Reis","year":"2017","journal-title":"Mol Neurobiol"},{"key":"10.1007\/s13311-019-00763-y_bib90","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neuroscience.2016.03.064","article-title":"BIIB021, a synthetic Hsp90 inhibitor, induces mutant ataxin-1 degradation through the activation of heat shock factor 1","volume":"327","author":"Ding","year":"2016","journal-title":"Neuroscience"},{"issue":"3","key":"10.1007\/s13311-019-00763-y_bib91","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.nbd.2008.10.016","article-title":"In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis","volume":"33","author":"Williams","year":"2009","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1007\/s13311-019-00763-y_bib92","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1006\/exnr.1999.7099","article-title":"Cerebellar allografts survive and transiently alleviate ataxia in a transgenic model of spinocerebellar ataxia type-1","volume":"158","author":"Kaemmerer","year":"1999","journal-title":"Exp Neurol"},{"issue":"42","key":"10.1007\/s13311-019-00763-y_bib93","doi-asserted-by":"crossref","first-page":"13126","DOI":"10.1523\/JNEUROSCI.0647-09.2009","article-title":"Grafting neural precursor cells promotes functional recovery in an SCA1 mouse model","volume":"29","author":"Chintawar","year":"2009","journal-title":"J Neurosci"},{"issue":"3","key":"10.1007\/s13311-019-00763-y_bib94","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s12311-013-0536-1","article-title":"Mesenchymal stem cells ameliorate cerebellar pathology in a mouse model of spinocerebellar ataxia type 1","volume":"13","author":"Matsuura","year":"2014","journal-title":"Cerebellum"},{"issue":"1","key":"10.1007\/s13311-019-00763-y_bib95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s13311-013-0235-0","article-title":"Surgical treatment of Parkinson's disease: patients, targets, devices, and approaches","volume":"11","author":"Wagle Shukla","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-019-00763-y_bib96","article-title":"Effectiveness of Deep Brain Stimulation (DBS) in Mice with Spinocerebellar Ataxia (SCA1). [abstract].","volume":"32","author":"Vedam-Mai","year":"2019","journal-title":"Mov Disord,"},{"issue":"11","key":"10.1007\/s13311-019-00763-y_bib97","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","article-title":"Scale for the assessment and rating of ataxia: development of a new clinical scale","volume":"66","author":"Schmitz-Hubsch","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-019-00763-y_bib98","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s12311-011-0316-8","article-title":"Ataxia rating scales--psychometric profiles, natural history and their application in clinical trials","volume":"11","author":"Saute","year":"2012","journal-title":"Cerebellum"},{"issue":"4","key":"10.1007\/s13311-019-00763-y_bib99","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s12311-017-0855-8","article-title":"NESSCA Validation and Responsiveness of Several Rating Scales in Spinocerebellar Ataxia Type 2","volume":"16","author":"Monte","year":"2017","journal-title":"Cerebellum"},{"issue":"11","key":"10.1007\/s13311-019-00763-y_bib100","doi-asserted-by":"crossref","first-page":"N105","DOI":"10.1088\/0967-3334\/37\/11\/N105","article-title":"Validity of a wearable accelerometer to quantify gait in spinocerebellar ataxia type 6","volume":"37","author":"Hickey","year":"2016","journal-title":"Physiol Meas"},{"issue":"1\u20132","key":"10.1007\/s13311-019-00763-y_bib101","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jns.2011.09.016","article-title":"Objective home-based gait assessment in spinocerebellar ataxia","volume":"313","author":"Subramony","year":"2012","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-019-00763-y_bib102","doi-asserted-by":"crossref","first-page":"12166","DOI":"10.1038\/srep12166","article-title":"Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression","volume":"5","author":"Southwell","year":"2015","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-019-00763-y_bib103","doi-asserted-by":"crossref","first-page":"413098","DOI":"10.1155\/2015\/413098","article-title":"Cerebrospinal Fluid Biomarkers in Spinocerebellar Ataxia: A Pilot Study","volume":"2015","author":"Brouillette","year":"2015","journal-title":"Dis Markers"},{"issue":"2","key":"10.1007\/s13311-019-00763-y_bib104","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12311-012-0405-3","article-title":"Magnetic resonance imaging biomarkers in patients with progressive ataxia: current status and future direction","volume":"12","author":"Currie","year":"2013","journal-title":"Cerebellum"},{"key":"10.1007\/s13311-019-00763-y_bib105","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.nbd.2014.11.011","article-title":"Assessing recovery from neurodegeneration in spinocerebellar ataxia 1: Comparison of in vivo magnetic resonance spectroscopy with motor testing, gene expression and histology","volume":"74","author":"Oz","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"10","key":"10.1007\/s13311-019-00763-y_bib106","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1523\/JNEUROSCI.5612-09.2010","article-title":"Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1","volume":"30","author":"Oz","year":"2010","journal-title":"J Neurosci"},{"issue":"Pt 3","key":"10.1007\/s13311-019-00763-y_bib107","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/brain\/aws369","article-title":"Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6","volume":"136","author":"Reetz","year":"2013","journal-title":"Brain"},{"issue":"7","key":"10.1007\/s13311-019-00763-y_bib108","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S1474-4422(13)70104-2","article-title":"Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data","volume":"12","author":"Jacobi","year":"2013","journal-title":"Lancet Neurol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00763-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-019-00763-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00763-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:50:22Z","timestamp":1761807022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923009649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":108,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1878747923009649"],"URL":"https:\/\/doi.org\/10.1007\/s13311-019-00763-y","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moving Towards Therapy in SCA1: Insights from Molecular Mechanisms, Identification of Novel Targets, and Planning for Human Trials","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-019-00763-y","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}